Regulatory Filings • Mar 6, 2015
Regulatory Filings
Open in ViewerOpens in native device viewer
Press Release Bagneux, France, Friday, March 6, 2015
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinicalstage specialty biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following upcoming investor conferences.
David Schilansky, Chief Operating Officer, will present at the 2015 Barclays Global Healthcare Conference on Tuesday, March 10, 2015, at 9:00 am ET in Miami, FL. DBV will also host investor meetings at the 8th Kempen & Co Healthcare & Life Sciences Conference on Thursday, April 16, 2015, in New York, NY.
A live audio webcast of the Barclays presentation will be available on the Investor Relations section of the company's website, http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will be available on DBV's website within 48 hours after the event.
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.
Susanna Mesa VP Finance, US Investor Relations & Strategy Tél. : +1 917-346-3447 [email protected]
Marion Janic US Media Relations Rooney & Associates Tél. : +1-212-223-4017 [email protected] Nathalie Donne Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.